Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Tesamorelin

Egrifta, TH9507

Quick Stats
Studies 64
Trials 24
Terminated PHASE2 INTERVENTIONAL NCT01388920

Efficacy and Safety Study of Tesamorelin in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Muscle Wasting

View on ClinicalTrials.gov Updated Dec 15, 2025

Brief Summary

A significant proportion of COPD subjects experience muscle wasting, which has been associated with increased morbidity, impaired physical functioning, and a poor quality of life. Muscle wasting is associated with reduced muscle strength in COPD subjects. In particular, weakness of peripheral muscles has been reported to play an important role in the reduced functional capacity and impaired exercise performance. The primary objective of this study is to investigate the effect of tesamorelin, in conjunction with exercise training, on lean body mass measured by dual energy x-ray absorptiometry (DXA) scan.

Interventions

Name: Tesamorelin
Type: DRUG
Description:
Name: Placebo
Type: DRUG
Description:

Primary Outcomes

Measure: Change From Baseline in Lean Body Mass at 6 Months
TimeFrame: 6 months
Description: The primary objective of the study was to evaluate the effect of tesamorelin on lean body mass by Dual-energy X-ray absorptiometry (DXA) scan

Trial Information

NCT ID

NCT01388920

Status

Terminated

Study Type

INTERVENTIONAL

Phases

PHASE2

Sponsor

Theratechnologies

Last Updated

December 15, 2025